The short version of cyclic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-07 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Orforglipron — brand name Foundayo — is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018. Orforglipron was approved for medical use in the United States in April 2026. It was approved for use in the UK in August 2026.
This deficit, approximately 15–20% lower than in nonsmokers, normalizes after about 3 months of abstinence. A 2016 study found that nicotine exposure creates long-lasting malleable circuits 7 months after the initial exposure to nicotine and 6 months after stopping its administration. Other studies suggest broader neuronal recovery, such as normalization of dopamine transporter (DAT) levels in reward centers, may extend up to 12–14 months in some cases of substance dependence affecting dopamine levels, though specific data for nicotine are limited.
== Prevalence and health effects == Lignans are the principal source of dietary phytoestrogens in typical Western diets, even though most research on phytoestrogen-rich diets has focused on soy isoflavones. Lignan's enterolignan products enterodiol and enterolactone have weak estrogenic activity, but they may also exert biological effects through non-estrogenic means. A 2021 review found that lignans have a positive effect on lipid profiles of patients with dyslipidemia related diseases. As of 2022, there is limited evidence that dietary intake of lignans is associated with a reduced cancer and cardiovascular disease risk.
Based on evidence from the geologic record, life most likely emerged on Earth between 4.32 and 3.48 Gya. In 2017, the earliest physical evidence of life was reported to consist of microbialites in the Nuvvuagittuq Greenstone Belt of Northern Quebec, in banded iron formation rocks at least 3.77 and possibly as old as 4.32 Gya. The micro-organisms could have lived within hydrothermal vent precipitates, soon after the 4.4 Gya formation of oceans during the Hadean. The microbes resemble modern hydrothermal vent bacteria, supporting the view that abiogenesis began in such an environment. Later research disputed this interpretation of the data, stating that the observations may be better explained by abiotic processes in silica-rich waters, "chemical gardens," circulating hydrothermal fluids, or volcanic ejecta. Biogenic graphite has been found in 3.7 Gya metasedimentary rocks from southwestern Greenland and in microbial mat fossils from 3.49 Gya cherts in the Pilbara region of Western Australia. Evidence of early life in rocks from Akilia Island, near the Isua supracrustal belt in southwestern Greenland, dating to 3.7 Gya, have shown biogenic carbon isotopes. In other parts of the Isua supracrustal belt, graphite inclusions trapped within garnet crystals are connected to the other elements of life: oxygen, nitrogen, and possibly phosphorus in the form of phosphate, providing further evidence for life 3.7 Gya.
Sources: en.wikipedia.org
Cancers are found to attract and rely on immune suppressors such as regulatory T cells or other cells in the tumor microenvironment to decrease the response of immune cells. Further, reducing the activity of cytotoxic T cells by sustaining expression of inhibitory receptors limits the effectiveness of immune checkpoint inhibitors. Cancers can modify the tumor microenvironment itself, creating physical and biochemical barriers to immune attack. Abnormal vasculature is a prominent way of doing this. Tumors secrete factors that attract the growth of blood vessels (angiogenesis) that encourages further methods of nutrient transport, feeding the tumor. Additionally, cancer cells can produce nerve growth factor which causes healthy neurons to develop around and within tumors. This is promotes further tumor growth because nerves produce neurotransmitters 5HT that prompt tumor cell proliferation. Essentially solid tumors are able to create networks of feedback loops, hijacking healthy cells.
== Processing of grains == The processing of grains helps to separate the bran and cereal germ, but may remove nutrients, such as B vitamins and dietary fiber. Processing is the modification of a grain or mixture of grains usually taking place in a facility remote from the location where the product is eaten. This distinguishes "breakfast cereals" from foods made from grains modified and cooked in the place where they are eaten.
Garden parsley is a bright green, biennial plant in temperate climates, or an annual herb in subtropical and tropical areas. Where it grows as a biennial, in the first year, it forms a rosette of tripinnate leaves 10–25 cm (3.9–9.8 in) long with numerous 1–3 cm leaflets, and a taproot used as a food store over the winter. In the second year, it grows a flowering stem to 75 cm (30 in) tall with sparser leaves and flat-topped 3–10 cm diameter umbels with numerous 2 mm diameter yellow to yellowish-green flowers. The seeds are ovoid, 2–3 mm long, with prominent style remnants at the apex. One of the compounds of the essential oil is apiole. The plant normally dies after seed maturation.
Emerson University, Multan (formerly Government Emerson College, Multan) is a public-sector university in Multan, Punjab, Pakistan. The institution traces its origins to 1920 and was reconstituted as a degree-awarding university in 2021 under the Emerson University Multan Act 2021 (Punjab Act VIII of 2021).
=== Pharmacodynamics === KNX-100 produces oxytocin-like effects, such as pro-social, anti-aggressive, and anti-addictive effects among others, in rodents and monkeys. The drug reduced self-administration of methamphetamine in rats by 85%, of cocaine in rhesus monkeys by 90%, and of alcohol in baboons by more than 50%. It is thought that KNX-100 may produce its antiaddictive effects by discounting drug reward in favor of social reward. In addition to its antiaddictive effects, KNX-100 reduces opioid withdrawal and nicotine withdrawal symptoms in animals. It appears to act to reduce opioid withdrawal symptoms by suppressing increased dynorphin/κ-opioid receptor signaling in the nucleus accumbens shell. Unexpectedly, KNX-100 did not show affinity for the oxytocin receptor nor act as an agonist, antagonist, or positive allosteric modulator of the receptor, but nonetheless robustly activates oxytocinergic signaling. In fact, KNX-100 can activate oxytocinergic signaling and cause associated effects to a greater extent than oxytocin itself. Screening at more than 100 different receptors and transporters was initially unable to identify the drug's biological target. It was suggested that KNX-100 may be acting at an upstream target to indirectly modulate the oxytocin system and increase oxytocin production. Subsequently, KNX-100 was said by its developers to have a novel undisclosed mechanism of action.
Sources: en.wikipedia.org
==== Toxicity of desomorphine ==== Animal studies comparing pure desomorphine to morphine showed it to have increased toxicity, more potent relief of pain, higher levels of sedation, decreased respiration, and increased digestive activity.
=== Ontogeny and life history === Neanderthal brain size at birth was similar to modern humans and constrained by the same obstetric factors; mothers giving birth to infants with heads too large to pass through the birth canal would be selected against. Growth in brain volume occurred at a faster pace in Neanderthal infants than in modern human infants, but growth of the brain did not reach completion earlier in Neanderthals than in modern humans owing to the larger brain size of the former. The rate of incisor crown formation in Neanderthals is also indicative of an accelerated pattern of life history relative to modern humans. Estimates of the age at weaning of Neanderthals vary. Barium levels in the enamel of a Belgian Neanderthal tooth from Scladina suggest a weaning age of 1.2 years. Trace element analysis of a Neanderthal tooth from Payre suggests that weaning occurred at about 2.5 years of age.
Bragg was influential in the effort to beat a leading American chemist, Linus Pauling, to the discovery of DNA's structure (after having been pipped at the post by Pauling's success in determining the alpha helix structure of proteins). At the same time Bragg's Cavendish Laboratory was also effectively competing with King's College London, whose Biophysics department was under the direction of Randall (Randall had refused Crick's application to work at King's College). Francis Crick and Maurice Wilkins of King's College were personal friends, which influenced subsequent scientific events as much as the close friendship between Crick and James Watson. Crick and Wilkins first met at King's College and not, as erroneously recorded by two authors, at the Admiralty during World War II. In 1995 Francis Crick signed the Ashley Montagu Resolution petitioning the International Court of Justice (previously the World Court) to help end genital mutation of children, including female genital mutilation, circumcision, and penile subincision.
Noyori devised a copper complex using a chiral Schiff base ligand, which he used for the metal–carbenoid cyclopropanation of styrene. In common with Knowles' findings, Noyori's results for the enantiomeric excess for this first-generation ligand were disappointingly low: 6%. However continued research eventually led to the development of the Noyori asymmetric hydrogenation reaction.
This proved that in aqueous solution, nobelium is most stable in the divalent state when strong oxidizers are absent. Later experimentation in 1974 showed that nobelium eluted with the alkaline earth metals, between Ca2+ and Sr2+. Nobelium is the only known f-block element for which the +2 state is the most common and stable one in aqueous solution. This occurs because of the large energy gap between the 5f and 6d orbitals at the end of the actinide series. It is expected that the relativistic stabilization of the 7s subshell greatly destabilizes nobelium dihydride, NoH2, and relativistic stabilisation of the 7p1/2 spinor over the 6d3/2 spinor mean that excited states in nobelium atoms have 7s and 7p contribution instead of the expected 6d contribution. The long No–H distances in the NoH2 molecule and the significant charge transfer lead to extreme ionicity with a dipole moment of 5.94 D for this molecule. In this molecule, nobelium is expected to exhibit main-group-like behavior, specifically acting like an alkaline earth metal with its ns2 valence shell configuration and core-like 5f orbitals. Nobelium's complexing ability with chloride ions is most similar to that of barium, which complexes rather weakly. Its complexing ability with citrate, oxalate, and acetate in an aqueous solution of 0.5 M ammonium nitrate is between that of calcium and strontium, although it is somewhat closer to that of strontium. The standard reduction potential of the E°(No3+→No2+) couple was estimated in 1969 to be between +1.4 and +1.5 V; it was later found in 2009 to be only about +0.75 V.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.